cudetaxestat

Cudetaxestat is a reversible, non-competitive small molecule inhibitor of autotaxin (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 protein), developed as an oral therapy for fibrotic diseases. Autotaxin is an enzyme that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA), a pro-fibrotic signaling molecule implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis. By allosterically inhibiting autotaxin, cudetaxestat reduces LPA production and downstream fibrotic signaling. The drug has demonstrated robust preclinical antifibrotic activity and favorable safety profiles in Phase 1 studies, both as monotherapy and in combination with approved IPF therapies such as nintedanib or pirfenidone[1][2][3][5][6][8]. Cudetaxestat has received Orphan Drug designation for both IPF and systemic sclerosis[2][7].

Other names

cudetaxestatBLD-0409BLD0409BLD 0409PAT 409PAT409PAT-409